Siemens Healthineers has reported a net income of €472m, or €0.42 per diluted share, for the third quarter ended 30 June 2024, a 5% rise compared to €451m, or €0.40 per diluted share, for the respective period in 2023.
The company’s net income for the third quarter of fiscal year 2024 (Q3 2024) increased by 9.5% compared to €431m, or €0.38 per diluted share for the second quarter of fiscal year 2024 (Q2 2024).
The medical technology company reported a revenue of €5.42bn for Q3 2024, a 4.3% rise compared to €5.2bn for the same quarter in 2023, and almost unchanged compared to Q2 2024.
Siemens Healthineers reported a gross profit of €2.09bn for Q3 2024, an 8% rise compared to €1.93bn for the respective quarter in the previous year.
The German company reported an income before tax of €595m for Q3 2024, a 15% increase compared to €516m for the same period in 2023.
Siemens Healthineers CEO Bernd Montag said: “We made good progress again in the third quarter, despite ongoing order delays in China. Varian and Diagnostics especially contributed to the strong operating performance. We confirm our outlook for the financial year.”
Siemens Healthineers’ imaging business reported a total adjusted revenue of €2.97bn for Q3 2024, a 4% rise compared to €2.86bn for the same quarter in 2023.
The company’s diagnostics division reported a total adjusted revenue of €1.10bn, a 1.5% increase compared to €1.09bn for the respective period in the previous year.
Siemens Healthineers’ company Varian reported a total adjusted revenue of €927m for Q3 2024, a 10.4% increase compared to €840m for the same period in 2023.
The German MedTech company’s advanced therapies unit reported a total adjusted revenue of €480m for Q3 2024, a 0.7% decline compared to €483m for the respective quarter in 2023.
Recently, Varian secured the US Food and Drug Administration (FDA) 510(k) clearance for a new functionality of its Ethos radiotherapy system.
